173034-70-3

Usage

Uses

Used in Pharmaceutical Applications:
[1-(1'(R)-ALPHA-METHYLBENZYL)-AZIRIDIN-2(R)-YL]-METHANOL is used as a pharmaceutical agent for its potential biological activity, which may include interactions with biological targets important for therapeutic effects.
Used in Chemical Research:
In the field of chemical research, [1-(1'(R)-ALPHA-METHYLBENZYL)-AZIRIDIN-2(R)-YL]-METHANOL serves as a subject for studying the properties and reactions of complex organic molecules, particularly those containing aziridine rings and alpha-methylbenzyl groups.
Used in Materials Science:
[1-(1'(R)-ALPHA-METHYLBENZYL)-AZIRIDIN-2(R)-YL]-METHANOL is utilized in materials science for exploring its potential in the development of new materials, possibly due to its solubility and reactivity, which could be harnessed for creating novel polymers or other advanced materials.

InChI:InChI=1/C11H15NO/c1-9(12-7-11(12)8-13)10-5-3-2-4-6-10/h2-6,9,11,13H,7-8H2,1H3/t9-,11-,12?/m1/s1

Upstream product

• 68820-82-6 (2R)-1[(R)-α-methylbenzyl]-2-aziridinecarboxylate ethyl ester 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 

Downstream Products

• 444814-32-8 4(S)-(chloromethyl)-3-(1'(R)-α-methylbenzyl)oxazolidin-2-one 
• 887947-03-7 (R)-1-[((R)-1-phenylethyl)aziridin-2-yl]methyl 4-methylbenzenesulfonate 
• 867153-75-1 (S)-4-iodomethyl-3-[(R)-1-phenylethyl]oxazolidine-2-one 
• 1093278-33-1 (R)-1-[((R)-1-phenylethyl)aziridin-2-yl]methyl methanesulfonate 
• 1082763-51-6 (E)-ethyl 3-((S)-1-((R)-1-phenylethyl)aziridin-2-yl)acrylate 
• 1458024-16-2 ((R)-3,4-dihydroxy-5-oxo-1-((R)-1-phenylethyl)pyrrolidin-2-yl)methyl acetate 
• 1316816-55-3 ((2R,3R,4S)-3,4-dihydroxy-5-oxo-1-((R)-1-phenylethyl)pyrrolidin-2-yl)methyl acetate 
• 1316816-58-6 (2R,3R,4R)-2-(hydroxymethyl)-1-((R)-1phenylethyl)pyrrolidine-3,4-diol 
• 1458024-17-3 ((2R,3S,4R)-3,4-dihydroxy-5-oxo-1-((R)-1-phenylethyl)pyrrolidin-2-yl)methyl acetate 
• 1458024-18-4 (2R,3S,4S)-2-(hydroxymethyl)-1-((R)-1-phenylethyl)pyrrolidine-3,4-diol 
• 1534390-94-7 (2R,3S)-ethyl 2,3-dihydroxy-3-((R)-1-((R)-1-phenylethyl)aziridin-2-yl)propanoate 
• 1534390-95-8 (R)-1-((R)-1-phenylethyl)-2-((1S,2S)-1,2,3-tris(benzyloxy)propyl)aziridine 
• 1534390-93-6 (2R,3S,4S)-3,4,5-tris(benzyloxy)-2-(((R)-1-phenylethyl)amino)pentan-1-ol 
• 1534390-96-9 (2S,3S,4S)-3,4,5-tris(benzyloxy)-2-(((R)-1-phenylethyl)amino)pentanoic acid 

Relevant academic research and scientific papers

SPHINGOLIPID DERIVATIVES AND THE COMPOSITION FOR ANTI-CANCER CONTAINING THE SAME

Disclosed are a novel sphingolipid derivative having a sphingosine kinase suppressing activity and a composition containing the same. When the newly synthesized sphingolipid derivative of the invention is used, it is possible to maintain concentrations of ceramide and sphingosine to be high by preventing ceramide and sphingosine from being phosphorylated due to sphingosine kinase since an activity of sphingosine kinase is suppressed. In addition, since the apoptosis is induced in a cancer cell by ceramide and sphingosine, it is possible to treat or prevent a cancer or disease related to the cancer. Further, it is possible to treat or prevent a hyper- proliferative disease such as cancer or proliferation-promoting activity of sphingosine kinase. Accordingly, the composition containing the same can be used as a composition for suppressing sphingosine kinase and a composition for treating or preventing a cancer or hyper-proliferative disease.

Regiospecific reductive ring cleavage of N-substituted aziridine-2-carboxylates and An aziridine-2-methanol via catalytic hydrogenation using Pd as a catalyst

Regiospecific reductive ring cleavage was accomplished in the reaction of N-α-methylbenzyl substituted aziridine-2-carboxylate and aziridine-2-methanol under a catalytic hydrogenation condition. The regiospecificity was determined by the substituent at C-